J&J Highlights Late-Stage R&D Prospects Across Pharma Division
Executive Summary
J&J says its success at integrating external and internal innovation, focus on understanding causes of disease and commercial excellence have helped its pharma subsidiary weather a $9 billion patent cliff and recoup growth prospects. One observation from its May 23 analyst meeting: seemingly more than most companies, Janssen systemically incorporates biomarkers and companion diagnostics beyond oncology into all of its core development programs.
You may also be interested in...
J&J’s Anti-IL-23 Guselkumab Phase III-Ready After Solid Psoriasis Results
Specific interleukin-23 blocker meets primary endpoint in Phase IIb dose-ranging study, paving the way for pivotal trials.
J&J’s Anti-IL-23 Guselkumab Phase III-Ready After Solid Psoriasis Results
Specific interleukin-23 blocker meets primary endpoint in Phase IIb dose-ranging study, paving the way for pivotal trials.
In A Competitive New Cancer Field, Infinity Looks For A Place To Play
Infinity presented positive efficacy data on its oral PI3 kinase inhibitor IPI-145 in CLL and lymphoma at ASCO, but other drug makers also released strong data on potential competitors that are further ahead in clinical development, sparking a stock sell off.